

## RESPONSE/ARGUMENT

This paper is in response to the Restriction Requirement mailed August 10, 2006.

The Examiner states that the present application is directed to more than one species of the generic invention and has required an election of a single disclosed species of compound and a single species of disorder to be treated.

Applicants elect, as the single compound species, the compound shown as Formula (Ib) in claim 17 wherein  $R^1=R^2=H$ ,  $X=Cl$  (at the ortho position) and the S enantiomer, i.e., with OH group going into the plane of paper as the structure is pictured. The following claims encompass this species; claims 1-32. (all)

Furthermore, Applicants elect as the single disclosed species of neurodegenerative disorders, acute neurodegenerative disorders associated with an abrupt insult resulting from hypoxia-ischemia as specifically claimed in claim 24. The following claims encompass this species of neurodegenerative disorder; claims 1-21, 24, 25, 28, 29 and 32.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

By: /Peter L. Herridge/  
PETER L. HERRIDGE  
Reg. No. 42,658

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-3385  
Dated: March 2, 2007  
Epm